Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Clinical safety and performance of a MRI conditional pacing system in patients undergoing cardiac MRI

View through CrossRef
AbstractBackgroundUtilization of cardiac magnetic resonance imaging (cMRI) as an imaging modality in clinical practice is rapidly increasing. More evidence from randomized studies establishing clinical safety and performance of pacing systems in patients undergoing a cMRI scan is needed.ObjectivesThe purpose of this prospective, multicenter, randomized study was to demonstrate safety and efficacy of the Accent MRI™ conditional pacing systems (St. Jude Medical, St. Paul, MN, USA) in patients undergoing cMRI scan.MethodsPatients (n  =  283) indicated for dual‐chamber pacemaker implant were randomized to either the MRI Group (MG) (n  =  140) or the Control Group (CG) (n  =  143) after successful device implantation of the Accent MRI™ system. Clinical evaluation and device interrogation were performed at pre‐ and post‐MRI scan, and 1 month post‐MRI for all patients. At 9–12 weeks postimplant, patients in MG underwent a nondiagnostic cMRI scan at 1.5 Tesla (T), while patients in CG underwent device interrogation and clinical evaluation twice with a 45‐minute waiting period in between. The safety endpoint was freedom from MRI scan‐related complications and that for efficacy was significant changes in right atrial/ventricular capture threshold and sensing amplitude between right before MRI, immediately after MRI, and 1 month post‐MRI.ResultsResults showed 100% freedom from MRI scan‐related complications. There were no significant changes in device performance between pre‐MRI scan and 1 month post‐MRI scan time points in both study groups.ConclusionscMRI scanning with 1.5 T scanners is safe in patients implanted with the Accent MRI™ conditional pacing system and has no significant effect on the electrical parameters of the device and leads.
Title: Clinical safety and performance of a MRI conditional pacing system in patients undergoing cardiac MRI
Description:
AbstractBackgroundUtilization of cardiac magnetic resonance imaging (cMRI) as an imaging modality in clinical practice is rapidly increasing.
More evidence from randomized studies establishing clinical safety and performance of pacing systems in patients undergoing a cMRI scan is needed.
ObjectivesThe purpose of this prospective, multicenter, randomized study was to demonstrate safety and efficacy of the Accent MRI™ conditional pacing systems (St.
Jude Medical, St.
Paul, MN, USA) in patients undergoing cMRI scan.
MethodsPatients (n  =  283) indicated for dual‐chamber pacemaker implant were randomized to either the MRI Group (MG) (n  =  140) or the Control Group (CG) (n  =  143) after successful device implantation of the Accent MRI™ system.
Clinical evaluation and device interrogation were performed at pre‐ and post‐MRI scan, and 1 month post‐MRI for all patients.
At 9–12 weeks postimplant, patients in MG underwent a nondiagnostic cMRI scan at 1.
5 Tesla (T), while patients in CG underwent device interrogation and clinical evaluation twice with a 45‐minute waiting period in between.
The safety endpoint was freedom from MRI scan‐related complications and that for efficacy was significant changes in right atrial/ventricular capture threshold and sensing amplitude between right before MRI, immediately after MRI, and 1 month post‐MRI.
ResultsResults showed 100% freedom from MRI scan‐related complications.
There were no significant changes in device performance between pre‐MRI scan and 1 month post‐MRI scan time points in both study groups.
ConclusionscMRI scanning with 1.
5 T scanners is safe in patients implanted with the Accent MRI™ conditional pacing system and has no significant effect on the electrical parameters of the device and leads.

Related Results

Hydatid Disease of The Brain Parenchyma: A Systematic Review
Hydatid Disease of The Brain Parenchyma: A Systematic Review
Abstarct Introduction Isolated brain hydatid disease (BHD) is an extremely rare form of echinococcosis. A prompt and timely diagnosis is a crucial step in disease management. This ...
e0650 The effects of biventricular synchronous pacing on CBF, MVO2 and CWE in dogs
e0650 The effects of biventricular synchronous pacing on CBF, MVO2 and CWE in dogs
Objective To compare the effects of biventricular synchronous pacing with different pacing site on coronary Blood flow (CBF), myocardial oxygen consumption (MVO2)...
GW24-e3507 Acute Effects of Rotation and Twist at Different Cardiac Pacing Sites Using Speckle Tracking Imaging
GW24-e3507 Acute Effects of Rotation and Twist at Different Cardiac Pacing Sites Using Speckle Tracking Imaging
Objectives Different cardiac site pacing may lead to different changes in the mechanics of left ventricular (LV) function, but how it affects LV rotation and twis...
Acute Changes in Cardiac Synchrony and Output According to RV Pacing Sites in Koreans with Normal Cardiac Function
Acute Changes in Cardiac Synchrony and Output According to RV Pacing Sites in Koreans with Normal Cardiac Function
Introduction: The synchrony of the pacing heart can be affected by the right ventricular (RV) pacing site and is crucial to cardiac function in pacemaker recipients. We evaluated t...
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Emerging Evidence of IgG4-Related Disease in Pericarditis: A Systematic Review
Abstract Introduction Immunoglobulin G4-related disease (IgG4-RD) is a recently identified immune-mediated condition that is debilitating and often overlooked. While IgG4-RD has be...
Changes in pacing variation with increasing race duration in ultra-triathlon races
Changes in pacing variation with increasing race duration in ultra-triathlon races
Abstract Background: Despite the increasing scientific interest in the relationship between pacing and performance in endurance sports, little information is available abou...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top